Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.
Pulm Pharmacol Ther. 2022 Jun;73-74:102127. doi: 10.1016/j.pupt.2022.102127. Epub 2022 Apr 14.
Pulm Pharmacol Ther. 2022.
PMID: 35429651
Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P, Kloska D, Pawlak S, Teska-Kaminska M, Galazka M, Bukato K, Pieczykolan A, Jaworski A, Molga-Kaczmarska A, Kopacz A, Badyra B, Kachamakova-Trojanowska N, Zolnierkiewicz O, Targosz-Korecka M, Poleszak K, Szymanik M, Zerek B, Pieczykolan J, Jozkowicz A, Grochot-Przeczek A.
Rozga P, et al. Among authors: teska kaminska m.
Int J Cancer. 2020 Aug 15;147(4):1117-1130. doi: 10.1002/ijc.32845. Epub 2020 Jan 24.
Int J Cancer. 2020.
PMID: 31863596
Free article.
Item in Clipboard
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J.
Bazydlo-Guzenda K, et al. Among authors: teska kaminska m.
Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4.
Mol Pharmacol. 2021.
PMID: 34349026
Item in Clipboard
AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
Pieczykolan JS, Kubiński K, Masłyk M, Pawlak SD, Pieczykolan A, Rózga PK, Szymanik M, Gałązka M, Teska-Kamińska M, Żerek B, Bukato K, Poleszak K, Jaworski A, Strożek W, Świder R, Zieliński R.
Pieczykolan JS, et al. Among authors: teska kaminska m.
Invest New Drugs. 2014 Dec;32(6):1155-66. doi: 10.1007/s10637-014-0153-y. Epub 2014 Sep 4.
Invest New Drugs. 2014.
PMID: 25182378
Item in Clipboard
Cite
Cite